Patents by Inventor Aaron Ciechanover
Aaron Ciechanover has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330064Abstract: The present disclosure provides mTOR agonists that selectively modulate proteasome dynamics, compositions, methods and uses thereof for modulation of stress-induced proteasome dynamics and related pathological conditions. The present disclosure specifically provides therapeutic methods for treating disorders associated with cytosolic accumulation of the proteasome. The invention further provides prognostic methods for detection and monitoring drug resistant cancers, as well as methods for screening for modulators of proteasome dynamics.Type: ApplicationFiled: July 8, 2021Publication date: October 19, 2023Inventors: Ido LIVNEH, Victoria COHEN-KAPLAN, Aaron CIECHANOVER, Gilad GOLDHIRSH, Yaniv ZOHAR, Noa LAVI, Bertrand Francois FABRE
-
Publication number: 20230095010Abstract: The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.Type: ApplicationFiled: August 15, 2022Publication date: March 30, 2023Applicant: Technion Research & Development Foundation Limited.Inventors: Aaron CIECHANOVER, Yelena KRAVTSOVA, Inna SHOMER, Victoria COHEN
-
Patent number: 11452759Abstract: The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.Type: GrantFiled: January 5, 2016Date of Patent: September 27, 2022Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITEDInventors: Aaron Ciechanover, Yelena Kravtsova, Inna Shomer, Victoria Cohen
-
Publication number: 20210348152Abstract: A peptide comprising the amino acid sequence set forth in WILVRLW (SEQ ID NO: 1), or any functionally related variant thereof, a complex, conjugate or chimera comprising the same, wherein the peptide is linked with or without a linker to RING or to a molecule or peptide that recruits E3 ligase and method for treating cancer by administering the same.Type: ApplicationFiled: November 27, 2019Publication date: November 11, 2021Inventors: Aaron CIECHANOVER, Yelena KRAVTSOVA, Gilad GOLDHIRSH
-
Publication number: 20180140667Abstract: The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.Type: ApplicationFiled: January 5, 2016Publication date: May 24, 2018Applicant: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCESInventors: Aaron CIECHANOVER, Yevgenia KRAVCHENKO, Inna SHOMER, Victoria COHEN
-
Patent number: 8263326Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: GrantFiled: August 8, 2008Date of Patent: September 11, 2012Assignee: Signal Pharmaceuticals, LLCInventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Publication number: 20090233855Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B? Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: ApplicationFiled: August 8, 2008Publication date: September 17, 2009Inventors: Anthony M. MANNING, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Patent number: 7507788Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.Type: GrantFiled: May 8, 2003Date of Patent: March 24, 2009Assignees: Rappaport Family Institute for Research in the Medical Sciences, Rockefeller InstituteInventors: Hermann Steller, Hyung Don Ryoo, Aaron Ciechanover, Hedva Gonen
-
Patent number: 7414120Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: GrantFiled: January 25, 2007Date of Patent: August 19, 2008Assignee: Signal PharmaceuticalsInventors: Anthony M. Manning, Frank Mercurio, Sharo Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Publication number: 20070208167Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: ApplicationFiled: January 25, 2007Publication date: September 6, 2007Inventors: Anthony Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Patent number: 7186503Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: GrantFiled: September 19, 2003Date of Patent: March 6, 2007Assignee: Signal Pharmaceuticals LLCInventors: Anthony M. Manning, Frank Mercurio, Sharo Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Publication number: 20060058229Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.Type: ApplicationFiled: May 8, 2003Publication date: March 16, 2006Inventors: Hermann Steller, Hyung Ryoo, Aaron Ciechanover, Hedva Gonen
-
Publication number: 20060003939Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.Type: ApplicationFiled: May 8, 2003Publication date: January 5, 2006Inventors: Hermann Steller, Hyung Ryoo, Aaron Ciechanover, Hedva Gonen
-
Publication number: 20040247589Abstract: The invention discloses anti-tumor activity in the sera of certain reptiles, more particularly in the serum of alligators or crocodiles. The active principle resides in one or more serum proteins or polypeptides that inhibit the growth of mammalian tumor cells in culture while being practically devoid of such inhibitory activity toward normal cells in culture. The active fractions obtained from the sera show no overt toxicity in healthy mammals, and this novel anti-tumor agent may therefore be used for the prevention, investigation, treatment or diagnosis of neoplasms.Type: ApplicationFiled: January 20, 2004Publication date: December 9, 2004Inventors: Ofer Binah, Aaron Ciechanover, Gila Maor
-
Publication number: 20040203098Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: ApplicationFiled: September 19, 2003Publication date: October 14, 2004Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Patent number: 6656713Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: GrantFiled: April 9, 2001Date of Patent: December 2, 2003Assignee: Signal Pharmaceuticals, Inc.Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Publication number: 20030166587Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.Type: ApplicationFiled: April 9, 2001Publication date: September 4, 2003Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
-
Patent number: 5932425Abstract: Compositions and methods for modulating the activation of nuclear factor .kappa.B (NF-.kappa.B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I.kappa.B.alpha. and/or I.kappa.B.beta.. Such compositions may be used for treating diseases associated with NF-.kappa.B activation. Modulating agents include peptides that comprise a recognition domain for E3 ubiquitin ligase.Type: GrantFiled: February 18, 1997Date of Patent: August 3, 1999Assignees: Signal Pharmaceuticals, Inc., Yissum Research Development Company of the Hebrew University of JerusalemInventors: Irit Alkalay, Yinon Ben-Neriah, Aaron Ciechanover, Anthony Manning, Frank Mercurio, Avraham Yaron